☆
Watchlist
Log in
Sign-up
Firebrick Pharma Ltd (fre) Logo

Firebrick Pharma Ltd (FRE)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)

FRE Chart

Snapshot

FRE's Principal Activity is the pharmaceutical development and manufacturing

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) +85.71%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,422 of 2,413
Sector Rank 120 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies VBS / NTI / ATH
EPS $0.00
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

FRE is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Firebrick Pharma Limited (FRE) is an Australian pharmaceutical developer focused on development and commercialisation of Nasodine, a anti-viral spray, designed to be an treatment and prevention of respiratory viral infections such as the common cold.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Creswick VIC 3363
Website www.firebrickpharma.com
Registry Automic Group
Auditor BDO (Audit) WA Pty Ltd
Date Listed 28 Jan 2022

Upcoming Calendar (Forecasted)

Date Event
10/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Phyllis Irene Gardner Non-Executive Director Nov 2020

Dr Phyllis Irene Gardner

Non-Executive Director

Dr Gardner is a tenured Professor of Medicine at Stanford University, as well as being on the Board of Fellows of Harvard Medical School. She has trained in internal medicine at Massachusetts General Hospital. After moving to Stanford in 1984, Phyllis was a scientific researcher, with her experience in medicine, pharmacology and drug delivery systems. After ten years in academia, she became interested in entrepreneurship, founding several biopharma ventures. From 1994 to 1998, she served as Principal Scientist and Head of Research at ALZA Corporation; and from 1999 to 2015, she was a partner at Essex Woodlands Health Ventures, an US venture capital firm focused on life sciences. She has been a director on numerous boards of US public biotech firms and is currently on the boards of MiMedx Group and CohBar.
Dr Peter Laurence Molloy Founder,Executive Chairman,Executive Director Apr 2012

Dr Peter Laurence Molloy

Founder,Executive Chairman,Executive Director

Dr Molloy has had a 17-year career in pharmaceutical marketing and general management. Overall, during his career and prior to Firebrick, he has been CEO of four biotechnology companies and head of four pharmaceutical subsidiaries. At the Australian pharmaceutical company, Faulding, he was a Product Manager and subsequently General Manager of the Medical Products Division and was responsible for the Betadine range in Australia, including the launch of Betadine Sore Throat Gargle. Subsequently, he served as head of two other Faulding subsidiaries (Faulding (USA) Inc. and Selby Scientific & Medical), before being recruited to Pharmacia (Pfizer) as Managing Director of Australia and NZ operations, where he managed pharmaceutical marketing, medical affairs and distribution. Then as Vice President of Strategic Marketing, he was responsible for Pharmacia's marketing strategy across 23 countries. Subsequently, he was CEO of several biotech companies in USA or Australia, where he managed R&D programs, moved drugs from research into human trials, and executed several pharmaceutical partnerships. During his tenure (7/2002 - 12/2005) as CEO of the ASX-listed antiviral drug development company Biota Holdings Limited. He was also founding CEO of Race Oncology Ltd (RAC) and listed that company on the ASX in July 2016. He resigned from RAC on 18 May 2020 and in 2014 he was also non-executive director of Viralytics Ltd and Parnell Pharmaceuticals.
Dr Stephen Francis Goodall Founder,Chief Operating Officer,Executive Director Apr 2012

Dr Stephen Francis Goodall

Founder,Chief Operating Officer,Executive Director

Dr Goodall has a background in pharmaceutical development, manufacturing, and regulatory and clinical strategy. Previously, he was Chief Operating Officer for Viralytics Ltd (ASX: VLA), where he was responsible for manufacturing, preclinical development, regulatory strategy, and human clinical trials through Phase 2. Prior to that, he was Chief Operating Officer for cBio, Director of Pharmaceutical Development at the inhaled pharmaceutical company, Vapotronics, where he managed all aspects of drug development and formulation; and as Director of Development at AGEN Biomedical, he was responsible for process development, scale-up and GMP manufacturing. Most recently, he was a Commercialisation Adviser to the Department of Industry, Innovation & Science. Previously, he has been an AC (Accelerating Commercialisation) Advisor to the Australian Government Department of Industry, Science, Energy and Resources.
Mr Stephen Buckley Company Secretary N/A
Show All

Director Interests

The current holdings of FRE directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Phyllis Gardner 13/11/2020 600,000 N/A N/A N/A
Stephen Goodall 12/04/2012 30,326,472 N/A N/A N/A
Peter Molloy 12/04/2012 30,326,472 N/A N/A N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Jan 18, 2022.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Aquarico Pty Ltd (P & C Molloy Family A/C) 30,326,472 17.96%
Biotech Design Pty Ltd 30,326,472 17.96%
Zero Nominees Pty Ltd 25,699,064 15.22%
Carina Management Pty Ltd (Carina Management A/C) 4,800,000 2.84%
Darius Kny 3,217,992 1.91%
Kashflow 18 Llc 2,795,508 1.66%
Mr Ivan Kaufman 2,550,000 1.51%
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd (Drp A/C) 2,140,000 1.27%
Mrs Karen Silbert (Peter Silbert Family A/C) 2,100,000 1.24%
Mr Richard Friedland 1,500,000 0.89%
Bt Portfolio Services Limited (Warrell Holdings S/F A/C) 1,500,000 0.89%
Dr Richard Harold Friedland 1,500,000 0.89%
Mr Paul Hartley Watts 1,450,000 0.86%
Mr Richard Lewis Abbott & Mrs Julie Ruth Abbott (Rl Abbott Super Fund A/C) 1,436,472 0.85%
Inyati Fund Pty Ltd 1,350,000 0.80%
Greensea Investments Pty Ltd 1,295,000 0.77%
Greenford Pty Ltd (Kluger Super Fund A/C) 1,200,000 0.71%
Asenna Wealth Solutions Pty Ltd 1,000,000 0.59%
Blake Nominees Pty Ltd (The M And T Super Fund A/C) 900,000 0.53%
Cromwell Investments Pty Ltd (Cromwell A/C) 896,472 0.53%
Stevens Brothers Pty Ltd 829,413 0.49%
Pheakes Pty Ltd (Senate A/C) 800,000 0.47%
Dr David Rosenfeld 780,000 0.46%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 0 0 19 188 147 354

Substantial Shareholders

No Substantial Shareholders for FRE in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
FRE Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.